Abstract | BACKGROUND: Treatment response to lipid-lowering therapy can vary in patients with the metabolic syndrome (MetS) due to various patient demographic and baseline characteristics. OBJECTIVE: METHODS: This is a post-hoc analysis of a multicenter, double-blind, randomized, 6-week parallel study in >1000 hypercholesterolemic subjects (median age of 59 years) with MetS and moderately high/high coronary heart disease risk who were treated with ezetimibe/ simvastatin (10/20 and 10/40 mg) or atorvastatin (10, 20, 40 mg). Factors that could affect these treatments were assessed by multivariate analysis. RESULTS: Increasing age, abdominal obesity (waist circumference ≥ 40/35 inches for men/women), and lower baseline hs-CRP were significant predictors of greater reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, triglycerides, and very-low-density lipoprotein cholesterol but not for changes in HDL-C or apolipoprotein AI; effects of race and baseline triglycerides, non-HDL-C, LDL-C, or HDL-C levels were more limited. Age ≥ 65 years (versus <65 years) was also associated with significantly greater attainment of all LDL-C and non-HDL-C targets, whereas abdominal obesity, gender (female > male) and lower baseline LDL-C, non-HDL-C, triglycerides, and hs-CRP were associated with improved attainment for some of these targets. Blood pressure, fasting glucose, Homeostasis Model Assessment of Insulin Resistance tertiles, and diabetes did not predict response for any efficacy variable. Ezetimibe/ simvastatin treatment (versus atorvastatin) was a significant predictor for change in most efficacy variables. CONCLUSIONS:
|
Authors | Jennifer G Robinson, Christie M Ballantyne, Willa A Hsueh, Jeffrey B Rosen, Jianxin Lin, Arvind K Shah, Joanne E Tomassini, Robert S Lowe, Andrew M Tershakovec |
Journal | Journal of clinical lipidology
(J Clin Lipidol)
2013 Jul-Aug
Vol. 7
Issue 4
Pg. 292-303
ISSN: 1933-2874 [Print] United States |
PMID | 23890516
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 National Lipid Association. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Anticholesteremic Agents
- Apolipoproteins B
- Azetidines
- Cholesterol, HDL
- Cholesterol, LDL
- Heptanoic Acids
- Pyrroles
- C-Reactive Protein
- Atorvastatin
- Simvastatin
- Ezetimibe
|
Topics |
- Adolescent
- Adult
- Age Factors
- Aged
- Anticholesteremic Agents
(therapeutic use)
- Apolipoproteins B
(blood)
- Atorvastatin
- Azetidines
(therapeutic use)
- C-Reactive Protein
(metabolism)
- Cholesterol, HDL
- Cholesterol, LDL
(blood)
- Double-Blind Method
- Ezetimibe
- Female
- Heptanoic Acids
(therapeutic use)
- Humans
- Male
- Metabolic Syndrome
(blood, drug therapy, metabolism)
- Middle Aged
- Obesity, Abdominal
(blood, physiopathology)
- Pyrroles
(therapeutic use)
- Simvastatin
(therapeutic use)
- Treatment Outcome
- Young Adult
|